Specify a stock or a cryptocurrency in the search bar to get a summary
ImmuCell Corporation
ICCCImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Address: 56 Evergreen Drive, Portland, ME, United States, 04103
Analytics
WallStreet Target Price
14 USDP/E ratio
–Dividend Yield
1.19 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ICCC
Dividend Analytics ICCC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ICCC
Stock Valuation ICCC
Financials ICCC
Results | 2019 | Dynamics |